Sentiment Summary
Recent Events
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
The ex-dividend date for Amgen's Q2 2026 dividend of $2.52 per share is scheduled for May 15, 2026. The dividend is payable on June 5, 2026, to shareholders of record on the ex-date scheduled.
The ex-dividend date for the Q2 2026 dividend of $1.73 per share, payable on June 10, 2026.
Received clinical trial approval from China's NMPA for HS-10541 tablets on 2026-05-13; estimated 5% impact due to innovative drug pipeline expansion.
The company is expected to receive Investigational New Drug (IND) approval from China's NMPA for SKB118; this pipeline milestone is estimated to have a 5% price impact as it validates the drug's potential expected.
Leerink Partners upgraded Johnson & Johnson stock to 'Outperform' from 'Market Perform' and raised its price target to $265 from $252, citing promising growth forecasts for new products Icotyde and Inlexzo; price impact estimated at 5% due to positive analyst sentiment forecasted.
Announced the global launch of the next-generation Shockwave C2 Aero coronary intravascular lithotripsy (IVL) catheter on 2026-05-13; price impact estimated at 5% due to market expansion expected.
Repurchased 1.78 million shares for approximately HKD 10.05 million on 2026-05-13. This is estimated to have a price impact of ≥1% expected.
Announced that the first subject has been dosed in the Phase 1 clinical trial of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor for autoimmune diseases. Early-stage clinical progress is estimated to have a low market impact (>1%).
The European Commission granted marketing authorization for HYMPAVZI (marstacimab) on 2026-05-13 for the treatment of adults and adolescents with hemophilia A or B with inhibitors (Low importance as a standard regulatory approval).
Global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS) for 13 early-stage programs in oncology, hematology, and immunology, with a potential value of up to $15.2 billion and upfront/near-term payments of $950 million; the high deal value is estimated to result in a price impact exceeding 10%, scheduled
Bristol-Myers Squibb announced a strategic collaboration with Hengrui Pharma on May 12, 2026, to develop 13 early-stage drug programs. BMS will pay $600 million upfront with a potential total deal value of up to $15.2 billion. No market reaction yet; high impact estimated due to the massive scale of the deal ($15.2B), scheduled.
Eli Lilly announced positive late-stage trial results showing patients maintained long-term weight loss by switching from high-dose injectable GLP-1s to lower-dose Zepbound or the oral pill Foundayo (orforglipron).
Announced that its associate, Legend Biotech (LEGN), reported strong Q1 2026 results on May 12, 2026, with CARVYKTI net sales increasing 62% year-over-year to approximately $597 million and a narrowed net loss.
Announced the exercise of its option to co-develop and share costs and profits/losses for its core drug candidate DB-1311/BNT324 in the U.S. market with partner BioNTech.
Executive President and Global Chief Medical Officer, Yongjiang Hei, was reported to have officially resigned to start his own venture. Estimated Low importance as executive changes in large firms often have limited immediate price impact.
Launched the TurboCHO™ Protein Expression Kit, a new reagent for antibody expression, at the PEGS Summit in Boston on May 12, 2026, aimed at accelerating drug discovery.
Announced an exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; analysts forecast high sales potential and a price impact of ≥10% forecasted.
Announced that its ADC drug SYS6010 was granted another Breakthrough Therapy Designation in China for treating esophageal squamous cell carcinoma. Estimated Low importance as breakthrough designations are positive but early-stage regulatory milestones.
IBI363 is expected to receive its third Breakthrough Therapy Designation from the NMPA on May 10, 2026; this clinical milestone's low market impact is expected
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
The sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab is expected to be accepted for review by China's NMPA; this regulatory progress is estimated to have a 5% price impact expected.
The European Commission granted approval for Sotyktu (deucravacitinib) for the treatment of active psoriatic arthritis in adults, announced on May 8, 2026. No market reaction yet; medium impact estimated due to expansion into the European market, scheduled.